Curaleaf Holdings Inc. (TSX: CURA) (OTCQX: CURLF) announced its board has authorized a share repurchase program to buy back up to 34.4 million subordinate voting shares over 12 months starting April 20, 2026.

The Toronto Stock Exchange approved the normal course issuer bid, which represents approximately 5% of the company's outstanding subordinate voting shares. Based on the April 14, 2026 closing price, the program has an aggregate value of approximately $83 million.

As of April 10, 2026, Curaleaf had 687.8 million subordinate voting shares outstanding. Under the program, the cannabis company can purchase up to 210,139 shares daily through TSX facilities, representing 25% of the average daily trading volume of 840,559 shares calculated over the six-month period ending March 31, 2026.

"This share repurchase program is a meaningful way to return value to our shareholders and reflects our confidence in the strength and durability of our strategy," said Boris Jordan, chairman and CEO of Curaleaf.

The company appointed ATB Cormark Capital Markets as its designated broker for the program. Purchases will occur at prevailing market prices and are expected to begin after Curaleaf releases first-quarter financial results. All repurchased shares will be canceled.

The program does not obligate Curaleaf to purchase a specific number of shares and may be modified or discontinued at any time according to securities legislation and TSX rules. The company has not repurchased any shares under a normal course issuer bid in the past 12 months.

Curaleaf operates as an international cannabis products provider with operations across medical and adult-use markets in multiple countries including the United States, Canada, Europe and Australia.